AR and neoplasm: Antigen-specific immune responses of these long-term survivors/tumor rejectors were assessed by IFNγ ELISpot, which again demonstrated immunodominant responses to the NTD peptide pool from BALB/c mice vaccinated with Ad-AR and Ad-AR-V7, as well as documenting the presence of long-term AR-specific immunity in vaccinated mice (Figure 2e).